Neuro-ophthalmic Complications of Modern Anti-cancer Drugs

Overview

Journal Graefes Arch Clin Exp Ophthalmol

Specialty Ophthalmology

Date 2024 Feb 12

PMID 38345654

Authors

Joshua A Oskam

Helen V Danesh-Meyer

Affiliations

Soon will be listed here.

Abstract

Purpose: Targeted cancer therapies have been responsible for a dramatic shift in treatment strategies for cancer, and the number of drugs, classes, and indications are continually growing. Neuro-ophthalmic complications of these medications are an uncommon but important subset of adverse events which profoundly impact vision. This review aims to collate studies and reports of known neuro-ophthalmic complications of targeted therapies and describe their management.

Methods: The anti-cancer drugs included in the review were any drugs targeting specific molecules involved in the cancer disease process. PubMed, EMBASE, and Web of Science were searched using the generic names of each drug and keywords of neuro-ophthalmic conditions. The prescribing information published by the US Food and Drug Administration (FDA) for each drug was also reviewed.

Results: Several classes of targeted anti-cancer drugs were found to cause neuro-ophthalmic adverse effects. Immune checkpoint inhibitors are responsible for a raft of immune-related adverse events such as optic neuritis, ischemic optic neuropathy, PRES, and myasthenia gravis. Therapies with anti-VEGF activity can provoke posterior reversible leukoencephalopathy, which commonly presents with visual loss and can be fatal if not treated promptly. Inhibitors of BCR-ABL1, VEGF, ALK, and proteasomes have all been linked to optic nerve disorders which can have debilitating consequences for vision.

Conclusion: The neuro-ophthalmic complications of modern anti-cancer drugs can limit or necessitate the withdrawal of these life-prolonging medications. Ophthalmologists should be alert for neuro-ophthalmic complications in these medications to facilitate prompt diagnosis and treatment and reduce the risk of severe and permanent consequences.

References

Lee H, Novitzky Basso I, Kim D . Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia. Int J Hematol. 2021; 113(5):632-641. DOI: 10.1007/s12185-021-03126-6. View

Serrano C, Bauer S . New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors. Curr Oncol Rep. 2022; 24(2):151-159. DOI: 10.1007/s11912-021-01165-0. View

Breccia M, Gentilini F, Cannella L, Latagliata R, Carmosino I, Frustaci A . Ocular side effects in chronic myeloid leukemia patients treated with imatinib. Leuk Res. 2007; 32(7):1022-5. DOI: 10.1016/j.leukres.2007.10.016. View

Govind Babu K, Attili V, Bapsy P, Anupama G . Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol. 2007; 27(1):43-4. DOI: 10.1007/s10792-007-9038-9. View

Rotstein D, Sawicka K, Bharatha A, Montalban X, Lipton J . CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases. Mult Scler. 2019; 26(9):1121-1124. DOI: 10.1177/1352458519892914. View

Rafei H, Jabbour E, Kantarjian H, Sinicrope K, Kamiya-Matsuoka C, Mehta R . Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. Leuk Lymphoma. 2019; 60(13):3292-3295. DOI: 10.1080/10428194.2019.1633635. View

Napolitano M, Santoro M, Mancuso S, Carlisi M, Raso S, Tarantino G . Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate. Clin Case Rep. 2017; 5(10):1573-1575. PMC: 5628210. DOI: 10.1002/ccr3.1137. View

Kwon S, Lee D, Kim Y . Optic disc edema as a possible complication of Imatinib mesylate (Gleevec). Jpn J Ophthalmol. 2008; 52(4):331-333. DOI: 10.1007/s10384-008-0561-7. View

Oh H, Cho M, Lee J, Jang P, Chung N, Cho B . Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia. Korean J Pediatr. 2013; 56(8):343-50. PMC: 3764259. DOI: 10.3345/kjp.2013.56.8.343. View

10.

Monge K, Galvez-Ruiz A, Alvarez-Carron A, Quijada C, Matheu A . Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case. Saudi J Ophthalmol. 2015; 29(3):227-31. PMC: 4487962. DOI: 10.1016/j.sjopt.2014.12.004. View

11.

Breccia M, Stagno F, Luciano L, Abruzzese E, Annunziata M, DAdda M . Dasatinib first-line: Multicentric Italian experience outside clinical trials. Leuk Res. 2015; 40:24-9. DOI: 10.1016/j.leukres.2015.11.008. View

12.

Schlemmer M, Bauer S, Schutte R, Hartmann J, Bokemeyer C, Hosius C . Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial. Eur J Med Res. 2011; 16(5):206-12. PMC: 3352192. DOI: 10.1186/2047-783x-16-5-206. View

13.

Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed R, Heldin C . Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001; 61(7):2929-34. View

14.

Biswas S, Zhao Y, Sandirasegarane L . Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3-kinase/Akt survival signaling in RGC-5 retinal ganglion cells. Mol Vis. 2009; 15:1599-610. PMC: 2728561. View

15.

Demichelis C, Balestra A, Lapucci C, Zuppa A, Grisanti S, Prada V . Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature. Neurol Sci. 2020; 42(4):1405-1409. PMC: 7955989. DOI: 10.1007/s10072-020-04604-1. View

16.

Kohler S, Keil T, Hoffmann S, Swierzy M, Ismail M, Ruckert J . CD4 FoxP3 T regulatory cell subsets in myasthenia gravis patients. Clin Immunol. 2017; 179:40-46. DOI: 10.1016/j.clim.2017.03.003. View

17.

Deryugina E, Quigley J . Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biol. 2015; 44-46():94-112. PMC: 5079283. DOI: 10.1016/j.matbio.2015.04.004. View

18.

Triplett J, Kutlubaev M, Kermode A, Hardy T . Posterior reversible encephalopathy syndrome (PRES): diagnosis and management. Pract Neurol. 2022; 22(3):183-189. DOI: 10.1136/practneurol-2021-003194. View

19.

Izzedine H, Ederhy S, Goldwasser F, Soria J, Milano G, Cohen A . Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009; 20(5):807-15. DOI: 10.1093/annonc/mdn713. View

20.

Bartynski W . Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol. 2008; 29(6):1043-9. PMC: 8118813. DOI: 10.3174/ajnr.A0929. View